EP0399429A1
(en)
|
1989-05-22 |
1990-11-28 |
Toray Industries, Inc. |
Anti-human interleukin-6 monoclonal antibody
|
JP2881311B2
(en)
|
1989-07-28 |
1999-04-12 |
味の素株式会社 |
Anti-human BCDF monoclonal antibody and method for quantifying human BCDF using the same
|
TW458985B
(en)
|
1993-05-31 |
2001-10-11 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human antibody against human interleukin-6
|
US5888510A
(en)
|
1993-07-21 |
1999-03-30 |
Chugai Seiyaku Kabushiki Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
EP0721783B1
(en)
|
1994-06-07 |
2005-03-16 |
Toray Industries, Inc. |
Preventive and remedy for diseases caused by fibrinoid or thrombus formation in the lung
|
US8017121B2
(en)
|
1994-06-30 |
2011-09-13 |
Chugai Seiyaku Kabushika Kaisha |
Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
|
JPH1066582A
(en)
|
1996-08-27 |
1998-03-10 |
Tosoh Corp |
Gene fragment or the like of antibody capable of recognizing helix d domain of il-6
|
CA2324115C
(en)
|
1998-03-17 |
2008-12-23 |
Chugai Seiyaku Kabushiki Kaisha |
A preventive or therapeutic agent for inflammatory bowel disease comprising il-6 antagonist as an active ingredient
|
US6395273B1
(en)
|
1998-06-10 |
2002-05-28 |
Promega Corporation |
Prevention and treatment of inflammatory bowel disease
|
IL145894A0
(en)
*
|
1999-04-29 |
2002-07-25 |
Novo Nordisk As |
Use of heparin-binding antagonists in the inhibition of bradykinin release
|
US7163681B2
(en)
|
2000-08-07 |
2007-01-16 |
Centocor, Inc. |
Anti-integrin antibodies, compositions, methods and uses
|
WO2002036164A1
(en)
|
2000-10-27 |
2002-05-10 |
Chugai Seiyaku Kabushiki Kaisha |
Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
|
EP2341060B1
(en)
|
2000-12-12 |
2019-02-20 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
US7658921B2
(en)
|
2000-12-12 |
2010-02-09 |
Medimmune, Llc |
Molecules with extended half-lives, compositions and uses thereof
|
PL374589A1
(en)
|
2001-06-28 |
2005-10-31 |
Pliva D.D. |
8/17 heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors
|
CN100374457C
(en)
|
2001-11-14 |
2008-03-12 |
森托科尔公司 |
Anti-IL-6 antibodies, compositions, methods and uses
|
EP1456347A4
(en)
|
2001-11-16 |
2006-08-02 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
FR2833011B1
(en)
|
2001-12-04 |
2004-10-29 |
Univ Claude Bernard Lyon |
NOVEL PROTEIN WITH IL-6 INHIBITING ACTIVITY
|
PT1517921E
(en)
|
2002-06-28 |
2006-09-29 |
Domantis Ltd |
DIFFERENTLY SPECIFIED LIGANDS WITH SEMI-LIFE IN THE INCREASED SERUM
|
US20060275294A1
(en)
|
2002-08-22 |
2006-12-07 |
Omoigui Osemwota S |
Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
|
US20060078533A1
(en)
|
2004-10-12 |
2006-04-13 |
Omoigui Osemwota S |
Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
|
KR100442281B1
(en)
|
2002-08-26 |
2004-08-02 |
엘지전자 주식회사 |
Method for controlling of Home Network System
|
CN1678744B
(en)
|
2002-08-30 |
2010-05-26 |
财团法人化学及血清疗法研究所 |
Human antihuman interleukin-6 antibody and fragment of the antibody
|
EP1572103A4
(en)
|
2002-11-15 |
2008-02-13 |
Centocor Inc |
Anti-angiogenic uses of il-6 antagonists
|
BRPI0403964B8
(en)
|
2003-04-04 |
2021-05-25 |
Genentech Inc |
stable liquid formulations, article of manufacture and use of these formulations for the treatment of ige-mediated dysfunction
|
EP1673396A1
(en)
|
2003-09-22 |
2006-06-28 |
BioVation GmbH & Co.KG. |
Use of antibodies for reducing the biological effectiveness of il-6
|
DE602005020743D1
(en)
|
2004-02-11 |
2010-06-02 |
Warner Lambert Co |
PROCESS FOR TREATING OSTEOARTHRITIS WITH ANTI-IL-6 ANTIBODIES
|
WO2006072954A2
(en)
|
2005-01-05 |
2006-07-13 |
Compugen Ltd. |
Novel il-6 polynucleotides encoding variant il-6 polypeptides and methods using same
|
JO3058B1
(en)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
Anti-IL-6 Antibodies,Compositions,Methods and uses
|
NZ563392A
(en)
|
2005-05-20 |
2009-12-24 |
Ablynx Nv |
Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
|
US8163881B2
(en)
|
2005-05-31 |
2012-04-24 |
The Board Of Regents Of The University Of Texas System |
Immunoglobulin molecules with improved characteristics
|
AR057582A1
(en)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
|
WO2007061029A1
(en)
|
2005-11-25 |
2007-05-31 |
Keio University |
Therapeutic agent for prostate cancer
|
DK1960430T3
(en)
|
2005-12-09 |
2015-01-05 |
Ucb Pharma Sa |
ANTIBODY MOLECULES THAT HAVE SPECIFICITY FOR HUMANT IL-6
|
WO2007074880A1
(en)
|
2005-12-28 |
2007-07-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing stabilizing preparation
|
JP2009521909A
(en)
|
2005-12-30 |
2009-06-11 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Anti-IL-6 antibody that inhibits binding of IL-6 and IL-6Rα complex to gp130
|
CA2644405A1
(en)
|
2006-03-13 |
2007-09-20 |
Ablynx N.V. |
Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
|
US7504106B2
(en)
|
2006-03-14 |
2009-03-17 |
Boris Skurkovich |
Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
|
JP2009545319A
(en)
|
2006-08-03 |
2009-12-24 |
バクシネックス,インコーポレーテッド |
Anti-IL-6 monoclonal antibody and use thereof
|
US20100129354A1
(en)
|
2006-10-27 |
2010-05-27 |
Ablynx N.V. |
Intranasal delivery of polypeptides and proteins
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
ES2433380T3
(en)
|
2006-11-30 |
2013-12-10 |
Medimmune Limited |
Specific antibodies to the interleukin 6 complex and the interleukin 6 receptor
|
JP4966647B2
(en)
|
2006-12-27 |
2012-07-04 |
矢崎総業株式会社 |
Seal structure of electrical junction box
|
CL2008000058A1
(en)
|
2007-01-09 |
2008-05-23 |
Wyeth Corp |
FORMULATION THAT INCLUDES AN ANTI-IL13 ANTIBODY, A CRIPROTECTOR, AND A DAMPING SOLUTION; PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT; METHOD TO TREAT AN IL13-RELATED DISORDER; AND PHARMACEUTICAL FORMS THAT UNDERSTAND IT.
|
RU2549701C2
(en)
|
2007-05-07 |
2015-04-27 |
Медиммун, Ллк |
Anti-icos antibodies and their application in treatment of oncological, transplantation-associated and autoimmune diseases
|
US7906117B2
(en)
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
DK2164514T3
(en)
|
2007-05-21 |
2017-02-27 |
Alderbio Holdings Llc |
Antibodies to IL-6 and its use
|
US20090238825A1
(en)
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
US20090104187A1
(en)
|
2007-05-21 |
2009-04-23 |
Alder Biopharmaceuticals, Inc. |
Novel Rabbit Antibody Humanization Methods and Humanized Rabbit Antibodies
|
US8404235B2
(en)
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
US9585899B2
(en)
|
2007-06-19 |
2017-03-07 |
The Johns Hopkins University |
Method of inhibiting platelet aggregation and clot formation
|
KR20100049568A
(en)
|
2007-06-26 |
2010-05-12 |
메디뮨 엘엘씨 |
Methods of treating rsv infections and related conditions
|
US9884899B2
(en)
|
2007-07-06 |
2018-02-06 |
Promedior, Inc. |
Methods for treating fibrosis using CRP antagonists
|
EP2187972B1
(en)
|
2007-08-16 |
2013-07-17 |
Carnegie Mellon University |
Inflammation-regulating compositions and methods
|
US20100203009A1
(en)
|
2007-10-02 |
2010-08-12 |
The Uab Research Foundation |
Pathway for Th-17 Cell Development and Methods Utilizing Same
|
PE20091174A1
(en)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
|
WO2009140348A2
(en)
|
2008-05-13 |
2009-11-19 |
Novimmune Sa |
Anti-il-6/il-6r antibodies and methods of use thereof
|
US8277804B2
(en)
|
2008-05-21 |
2012-10-02 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
US8188235B2
(en)
*
|
2008-06-18 |
2012-05-29 |
Pfizer Inc. |
Antibodies to IL-6 and their uses
|
TWI440469B
(en)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
WO2010065079A2
(en)
|
2008-11-25 |
2010-06-10 |
Alder Biopharmaceuticals, Inc. |
Antibodies to il-6 and use thereof
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
KR20110108398A
(en)
|
2009-01-29 |
2011-10-05 |
메디뮨 엘엘씨 |
Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
|
CN102740888B
(en)
*
|
2009-11-24 |
2016-10-12 |
奥尔德生物制药公司 |
IL-6 antibody and application thereof
|
JO3417B1
(en)
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
|
US20130224109A1
(en)
|
2010-07-20 |
2013-08-29 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods featuring il-6 and il-21 antagonists
|
NZ609557A
(en)
|
2010-10-06 |
2014-12-24 |
Regeneron Pharma |
Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
|
EP3351559A3
(en)
*
|
2010-11-08 |
2018-10-31 |
F. Hoffmann-La Roche AG |
Subcutaneously administered anti-il-6 receptor antibody
|
US20120189621A1
(en)
|
2011-01-21 |
2012-07-26 |
Yann Dean |
Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
|
JP6097702B2
(en)
|
2011-03-03 |
2017-03-15 |
アペクシジェン, インコーポレイテッド |
Anti-IL-6 receptor antibody and method of use thereof
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
EP3586862B1
(en)
|
2012-10-22 |
2021-12-08 |
Stealth Peptides International, Inc. |
Methods for reducing risks associated with heart failure and factors associated therewith
|
KR20150070384A
(en)
|
2012-10-25 |
2015-06-24 |
메디뮨 엘엘씨 |
Stable, low viscosity antibody formulation
|
SG10201608703SA
(en)
|
2012-11-08 |
2016-12-29 |
Eleven Biotherapeutics Inc |
Il-6 antagonists and uses thereof
|
KR20150083117A
(en)
|
2012-11-08 |
2015-07-16 |
클리어사이드 바이오메디컬, 인코포레이드 |
Methods and devices for the treatment of ocular disease in human subjects
|
MX359794B
(en)
|
2013-03-15 |
2018-10-10 |
Intrinsic Lifesciences Llc |
Anti-hepcidin antibodies and uses thereof.
|
US10745475B2
(en)
*
|
2013-08-30 |
2020-08-18 |
Takeda Gmbh |
Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
|
US20160130340A1
(en)
|
2013-10-07 |
2016-05-12 |
Alderbio Holdings Llc |
Dosing regimens using anti-il-6 antibodies for the treatment of rheumatoid and psoriatic arthritis
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
UY36449A
(en)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
|
JP2018529756A
(en)
|
2015-07-31 |
2018-10-11 |
メディミューン リミテッド |
Methods for treating hepcidin-mediated disorders
|
EP3576790A4
(en)
|
2017-02-01 |
2020-12-23 |
Yale University |
Treatment of diuretic resistance
|
BR112020013519A2
(en)
|
2018-01-05 |
2020-12-01 |
Corvidia Therapeutics, Inc |
method for treating an inflammation.
|